Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Kopin Corp (KOPN)

Kopin Corp (KOPN)
1.3550 -0.0250 (-1.81%) 14:34 ET [NASDAQ]
1.3500 x 1605 1.3600 x 3219
Realtime by (Cboe BZX)
1.3500 x 1605 1.3600 x 3219
Realtime 1.3800 unch (unch) 09:19 ET
Quote Overview for Thu, Mar 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3650
Day High
1.4100
Open 1.3700
Previous Close 1.3800 1.3800
Volume 532,621 532,621
Avg Vol 2,204,251 2,204,251
Stochastic %K 62.25% 62.25%
Weighted Alpha -14.83 -14.83
5-Day Change +0.0550 (+4.20%) +0.0550 (+4.20%)
52-Week Range 0.5610 - 2.1697 0.5610 - 2.1697
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,145
  • Shares Outstanding, K 158,801
  • Annual Sales, $ 40,390 K
  • Annual Income, $ -19,750 K
  • EBIT $ -48 M
  • EBITDA $ -47 M
  • 60-Month Beta 2.74
  • Price/Sales 3.71
  • Price/Cash Flow N/A
  • Price/Book 9.23

Options Overview Details

View History
  • Implied Volatility 149.01% ( -18.38%)
  • Historical Volatility 85.53%
  • IV Percentile 61%
  • IV Rank 19.20%
  • IV High 671.03% on 04/17/24
  • IV Low 24.93% on 06/17/24
  • Put/Call Vol Ratio 3.65
  • Today's Volume 223
  • Volume Avg (30-Day) 2,010
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 67,393
  • Open Int (30-Day) 62,858

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1600 +17.67%
on 03/04/25
Period Open: 1.5800
1.6400 -16.77%
on 02/21/25
-0.2150 (-13.61%)
since 02/20/25
3-Month
1.0800 +26.39%
on 01/13/25
Period Open: 1.2900
2.1697 -37.09%
on 01/24/25
+0.0750 (+5.81%)
since 12/20/24
52-Week
0.5610 +143.32%
on 09/23/24
Period Open: 1.9400
2.1697 -37.09%
on 01/24/25
-0.5750 (-29.64%)
since 03/20/24

Most Recent Stories

More News
Kopin Stock Pops On ‘Buy’ Rating From Canaccord: Retail Remains Undecided

After a challenging year, Kopin’s defense-focused projects and medical tech developments signal strong growth potential, according to Cannacord’s research note.

KOPN : 1.3550 (-1.81%)
IWC : 117.08 (-0.16%)
VTI : 278.00 (-0.50%)
Kopin: Q3 Earnings Snapshot

Kopin: Q3 Earnings Snapshot

KOPN : 1.3550 (-1.81%)
Kopin to Present at the MicroCap Rodeo Fall Conference

NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Kopin Corporation (NASDAQ:KOPN) a leading provider of application-specific optical systems and high-performance microdisplays for defense, enterprise, industrial,...

KOPN : 1.3550 (-1.81%)
Kopin: Q2 Earnings Snapshot

Kopin: Q2 Earnings Snapshot

KOPN : 1.3550 (-1.81%)
Kopin: Q1 Earnings Snapshot

Kopin: Q1 Earnings Snapshot

KOPN : 1.3550 (-1.81%)
Kopin: Q4 Earnings Snapshot

Kopin: Q4 Earnings Snapshot

KOPN : 1.3550 (-1.81%)
Kopin: Q3 Earnings Snapshot

Kopin: Q3 Earnings Snapshot

KOPN : 1.3550 (-1.81%)
Kopin Corporation to Present at LD Micro: Sweet Sixteen Main Event Investor Conference

Westborough, Massachusetts--(Newsfile Corp. - September 26, 2023) - Kopin Corporation (NASDAQ: KOPN) a leading provider of application specific optical systems and high performance micro-displays for defense,...

KOPN : 1.3550 (-1.81%)
Kopin Gains on National Defense Order

Kopin Corporation (NASDAQ: KOPN) noted its shares were on the move upward Monday. The company, a leading ...

KOPN : 1.3550 (-1.81%)
Kopin: Q2 Earnings Snapshot

Kopin: Q2 Earnings Snapshot

KOPN : 1.3550 (-1.81%)
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
BINV : 34.07 (-1.62%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China

LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

BINV : 34.07 (-1.62%)
CASI : 2.36 (+2.61%)
Pre-Market Brief: Stocks See Support from Dovish Chinese Policy News

Morning Markets Dec S&P 500 futures this morning are up by +0.21%. Stocks are seeing support from a rally in Chinese stocks today on signs that China’s central bank may soon ease monetary policy. In...

MRNA : 32.93 (-1.17%)
VG : 11.65 (+4.02%)
GFS : 37.80 (-2.05%)
CASI : 2.36 (+2.61%)
ASTR : 0.5390 (-2.00%)
ATVI : 94.42 (-0.05%)
PGNY : 21.74 (+0.14%)
AUPH : 8.34 (-0.36%)
CASI Pharmaceuti­­­cals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026

Palm Beach, FL – August 24, 2021 – FinancialNewsMedia.com News Commentary – Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense...

QBIO : 0.0001 (unch)
ABVC : 0.6659 (+0.89%)
TRIL : 18.44 (+2.62%)
CASI : 2.36 (+2.61%)
SESN : 12.5760 (+7.29%)
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
BINV : 34.07 (-1.62%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China

LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

BINV : 34.07 (-1.62%)
CASI : 2.36 (+2.61%)
Pre-Market Brief: Stocks See Support from Dovish Chinese Policy News

Morning Markets Dec S&P 500 futures this morning are up by +0.21%. Stocks are seeing support from a rally in Chinese stocks today on signs that China’s central bank may soon ease monetary policy. In...

MRNA : 32.93 (-1.17%)
VG : 11.65 (+4.02%)
GFS : 37.80 (-2.05%)
CASI : 2.36 (+2.61%)
ASTR : 0.5390 (-2.00%)
ATVI : 94.42 (-0.05%)
PGNY : 21.74 (+0.14%)
AUPH : 8.34 (-0.36%)
CASI Pharmaceuti­­­cals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026

Palm Beach, FL – August 24, 2021 – FinancialNewsMedia.com News Commentary – Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense...

QBIO : 0.0001 (unch)
ABVC : 0.6659 (+0.89%)
TRIL : 18.44 (+2.62%)
CASI : 2.36 (+2.61%)
SESN : 12.5760 (+7.29%)

Business Summary

Kopin Corporation is a leading developer and provider of innovative wearable technologies and solutions for integration into head-worn computing and display systems to military, industrial and consumer customers. Kopin's technologies and solutions are available as components providing individual capabilities...

See More

Key Turning Points

3rd Resistance Point 1.5433
2nd Resistance Point 1.4867
1st Resistance Point 1.4333
Last Price 1.3550
1st Support Level 1.3233
2nd Support Level 1.2667
3rd Support Level 1.2133

See More

52-Week High 2.1697
Fibonacci 61.8% 1.5552
Fibonacci 50% 1.3654
Last Price 1.3550
Fibonacci 38.2% 1.1755
52-Week Low 0.5610

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.